Inspire Investing 13F: Exits Astrana Health (ASTH) Stake

Inspire Investing closed out its entire position in Astrana Health, Inc. ASTH by selling all 57,024 shares it held, according to a Form 13F filing disclosed on October 22, 2026.

ASTH Astrana Health, Inc.

$37.45 ▲ +48.49% year to date

1M 3M YTD

Daily close · Oct 23, 2026

Inside Inspire Investing's Astrana Health Trade

Prior to the filing, Inspire Investing held 57,024 shares of the healthcare provider. The complete exit dropped its stake to zero shares.

Other Institutional Activity in Astrana Health

Other institutional funds have also adjusted their holdings in the medical care provider. For example, 325 Capital Llc reduced its holdings by 225,294 shares, ending with 1,613,843 shares worth about $60,438,421 in a report covering the period ending June 30, 2026.

Astrana Health, Inc. Stock Up 0.3%

Astrana Health, Inc. recently traded around $37.45 as of October 24, 2026. That puts the stock about 0.2% above its 50-day moving average of $37.37 and roughly 11.6% above its 200-day moving average of $33.57. Shares sit 27.4% below their 52-week high of $51.60 and well above their 52-week low of $18.08.

Recent Earnings

Astrana Health reported trailing twelve month revenue of $3,844,193,024 alongside trailing earnings of $0.83 per share. The company generated a net profit margin of 1.1% and a return on equity of 6.9%. The company's next earnings report is scheduled for November 5, 2026.

Analysts Set New Price Targets

Wall Street firms maintain an active outlook on the stock. On July 14, 2026, TD Cowen maintained a buy rating on the stock while lifting its target to $50.00 from $45.00. Later, on August 7, 2026, Barclays maintained an overweight rating while raising its target to $53.00 from $50.00. Truist Securities maintained a buy rating on August 11, 2026, lifting its target to $55.00 from $47.00. Oppenheimer initiated coverage on September 15, 2026, with an outperform rating and a $53.00 price target. Freedom Capital Markets maintained a buy rating on October 1, 2026, with a $50.00 price target. Overall, the stock carries a strong buy recommendation from nine analysts with a mean price target of $51.67.

About Astrana Health

Astrana Health, Inc. operates as a healthcare management company that provides medical care services throughout the United States. The business is organized across three primary segments focused on care partners, care delivery, and care enablement. It delivers care coordination services connecting patients, families, primary care doctors, specialists, and health plans.

Bottom Line

Investors tracking Astrana Health will want to watch the upcoming earnings release scheduled for November 5, 2026, to gauge how current margins and revenues align with institutional portfolio changes.